A subgroup analysis of the PUSH trial sought to answer the research question: Does an incremental increase in urine volume provide benefit at different levels of baseline urine volume?

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has fired two key leaders of the task force that sets insurance coverage rules. Dr. John Wong, ...

Topline results from the phase 3 REDUCE 2 trial show that investigational pozdeutinurad effectively lowers serum uric acid in adults with gout.

Individuals with diabetes are at an increased risk of developing dementia, according to a study published in the June issue of Diabetes, Obesity and Metabolis ...

The Expander-2 trial randomly assigned men with BPH symptoms at 23 sites in the US and Canada to receive a temporary nitinol urethral implant, Urocross Expander, or a sham procedure.

Active repetitive transcranial magnetic stimulation also linked to lower societal costs, higher QALYs than sham.

An investigator reported 10-year follow-up data from a phase 3 trial of extended vs limited pelvic lymph node dissection during radical prostatectomy.

Relative increase of 8.2 percent in odds of complications seen for every 10-µg/m3 increase in the highest single-day 24-hour PM2.5 exposure.

The FDA has granted Priority Review to finerenone (Kerendia) for adults with type 1 diabetes and CKD, following FINE-ONE trial data showing a 25% reduction in UACR.

The FDA is reviewing an sBLA for nogapendekin alfa inbakicept-pmln plus BCG to treat BCG-unresponsive NMIBC with papillary disease without CIS.

Genitourinary adverse events seen in both groups; similarly, very low rates of gastrointestinal adverse events seen with 2F SBRT, 5F SBRT.